Beryl Drugs has informed that with reference to various conditions stipulated under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other regulation required to be complied by the listed Companies, it enclosed the Compliance Certificate under Regulation 74(51 for the quarter ended 10th September, 2023.
The above information is a part of company’s filings submitted to BSE.